Replies to post #171227 on Biotech Values

[DewDiligence]

KIN—It’s reasonable to surmise that the 40% pop today is related, at least in part, to the outsized performance of PETX since its own IPO.

[DewDiligence]

KIN -28% AH on discontinuation of lead program—AtoKin for canine atopic dermatitis:

http://finance.yahoo.com/news/kindredbio-announces-atokin-atopic-dermatitis-210100743.html

The reason cited for the discontinuation is new competition, which suggests poor planning by somebody.